Compare Comcast Corporation (CMCSA) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Comcast Corporation vs Crispr Therapeutics AG — how do they compare? Comcast Corporation trades at $25.22 (market cap $91.02B), while Crispr Therapeutics AG trades at $53.93 (market cap $5.23B). The key difference: Comcast Corporation is far larger — about 17.4× Crispr Therapeutics AG's market cap, and Comcast Corporation pays a 5.15% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CMCSA | CRSP | |
|---|---|---|
Market Cap | $91.02B | $5.23B |
Sector | Media | Health |
52-Week High | $32.50 | $76.78 |
52-Week Low | $21.92 | $44.34 |
Enterprise Value | $173.74B | $3.65B |
Dividend Yield | 5.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Comcast (CMCSA) trades at $25.20, down 0.63% today, with strong fundamentals including a P/E of 8.22 and net income margin of 8.97%. The stock shows bullish technical signals with moving averages supporting upward momentum, though RSI indicates potential overbought conditions. Recent earnings beats and a planned NBCUniversal spinoff provide positive catalysts, while analyst consensus remains strongly bullish with a $27.78 price target.
CMCSA presents compelling value with discounted valuation multiples and consistent cash flow generation. Key opportunities include wireless growth and media separation, while risks involve competitive pressures and potential economic headwinds affecting consumer spending. The stock offers a balanced risk-reward profile for long-term investors seeking stable returns.
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Comcast Corporation
Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to roughly 61 million U.S. homes and businesses, or nearly half of the country. About 56% of the homes in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC broadcast network, several local NBC affiliates, Universal Studios, and several theme parks. Sky, acquired in 2018, is the dominant television provider in the U.K. and has invested heavily in exclusive and proprietary content to build this position. The firm is also the largest pay-television provider in Italy and has a presence in Germany and Austria.
Read more on CMCSA →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
